SUMMARY
INTRODUCTION
A major focus in the study of gene regulation involves the mechanisms by which the cell achieves specific activation of endogenous chromosomal genes. In addressing this issue, rationally designed components of the transcriptional machinery can provide powerful tools for testing our understanding of gene regulation (1) (2) (3) . In particular, artificial transcription factors -targeted to novel sequences within a given locus and bearing functional domains of the experimenter's choosing -may prove especially useful since they offer the prospect of complete recapitulation of any given activation process using totally defined components. Artificial transcription factors may also provide practical benefits in areas such as medicine and biotechnology.
The DNA binding motif of choice that has emerged for achieving specific recognition of predetermined, desired DNA sequences is the Cys2-His2 zinc finger. Over the past decade, selection and design studies have demonstrated the adaptability of this motif and have yielded simple, powerful strategies for designing zinc finger proteins (ZFPs) 1 that can bind specifically to virtually any DNA sequence (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . More recently, ZFPs with engineered DNA sequence specificities have begun to be used as artificial transcription factors to regulate endogenous chromosomal genes (16) (17) (18) . The growing use of these designed ZFPs has led to an appreciation of the role of chromatin structure 6 We find that this strategy has yielded eight distinct ZFPs targeted to seven 9-bp sites that activate VEGF-A expression, and that for certain ZFPs linkage to activation domains from either VP16 or p65 provides differing levels of activation dependent on the chromosomal site that is targeted. Furthermore, when certain combinations of our VP16 and p65-linked ZFPs targeted to distinct chromosomal sites are cotransfected the observed VEGF-A activation is more than additive relative to the activation levels of the individual ZFPs. Finally, we show that the levels of activation achieved by these engineered transcription factors exceed VEGF-A levels attained during the hypoxic response and that the relative proportions of VEGF-A splice variants produced by this activation closely approximates normal splice variant ratios seen in these cells.
EXPERIMENTAL PROCEDURES

Mapping of DNase 1 -accessible chromatin regions in the VEGF-A locus -
Immortalized cell lines used in these studies (HEK293, Hep3B, and H9c2(2-1)) were obtained from the American Type Culture Collection and human primary skeletal muscle cells were obtained from Clonetics. Each line was maintained essentially as recommended by the suppliers. Rat primary cardiac myocytes were recovered from the hearts of day 1 neonatal Wistar-Han rats (Charles River) via dissociation with a solution of 115 U/ml type II collagenase and 0.08% pancreatin. They were then purified on a discontinuous Percoll gradient, resuspended in a plating medium containing 15% Activation of Vascular Endothelial Growth Factor A 9 VEGF-A gene was directly fused with the luciferase gene in this construct. HEK293 cells were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum in a 5% CO 2 incubator at 37°C. Cells were plated in 24-well plates at a density of 160,000 cells per well a day before transfection. The VEGF-A reporter construct and ZFP-VP16 fusion plasmid were co-transfected into the cells via LipofectAMINE reagent (Gibco Life Technologies) according to manufacturer's recommendations, using 1.5 µl LipofectAMINE reagent, 260 ng of the VEGF-A reporter construct, 30 ng of plasmid DNA encoding ZFP-VP16, and 10 ng of control pRL-CMV plasmid (Promega). Medium was removed and replaced with fresh medium 16 hours after transfection. Forty hours after transfection, medium was removed, and the cells were harvested and assayed for luciferase reporter activity using the Dual-luciferase Assay System (Promega) according to manufacture's protocol.
Assay for activity of ZFP fusions for endogenous VEGF-A activation in human cells by
transient transfection  HEK293 cells were plated in 24-well plates at a density of 160,000 cells per well and grown as described above. A day later, plasmids encoding ZFP-VP16 fusion were transfected into the cells using LipofectAMINE reagent (Gibco Life Technologies) according to manufacture's recommendations, using 1.5 µl LipofectAMINE reagent and 0.3 µg ZFP plasmid DNA per well. Medium was removed and replaced with fresh medium 16 hours after transfection. Forty hours after transfection, the culture medium and the cells were harvested and assayed for VEGF-A expression. VEGF-A protein contents in the culture medium were assayed using a human VEGF-A ELISA kit (R&D Systems) according to manufacture's protocol.
For Western analysis of ZFP protein expression, cells were lysed with Laemmli Sample Loading Buffer and the lysates were analyzed via electrophoresis on a 10% polyacrylamide gel (BioRad) followed by Western blotting using anti-FLAG M2 monoclonal antibody (Sigma) which recognizes the FLAG epitope tag of the engineered ZFPs. The Western blots were visualized by ECL (Amersham Phamacia Biotech) as described previously (17).
For quantitative RT-PCR analysis of VEGF-A mRNA level, the cells were lysed and total RNAs were prepared using the RNeasy Total RNA Isolation Kit with in-column DNase treatment (Qiagen). Twenty five ng RNA were used in real-time quantitative RT-PCR analysis using Taqman chemistry on an ABI 7700 SDS machine (Perkin Elmer Applied Biosystems) as described previously (17). Briefly, reverse transcription was performed at 48°C for 30 min using MultiScribe Reverse Transcriptase (Perkin Elmer). Following a 10 min denaturation at 95°C, PCR amplification using AmpliGold DNA polymerase was conducted for 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute. The results were analyzed using SDS version 1.6.3 software. The primers and probes used for Taqman analysis were listed in Table I . The primers and probe used for human VEGF-A recognize all known splice variants.
Northern and Splice variants analysis  HEK293 cells were grown in 150mm dishes and transfected with pcDNA3 vector control or ZFP using LipofectAMINE reagent (Gibco Life Technologies) according to manufacture's recommendations. Cells and conditioned medium were harvested 40 hours after transfection. Total RNA was extracted from the cells using Trizol reagent (Gibco Life Technologies) followed by RNeasy total RNA isolation midi-prep system (Qiagen). For Northern analysis of VEGF-A mRNA expression, various total RNA samples (30 µg) were resolved on a 1.2%
formaldehyde agarose gel and blotted onto a Nytran SuperCharge membrane (Schleicher & Schuell). The membrane was hybridized to 32 P-labeled human VEGF-A-165 cDNA antisense riboprobe at 68°C in Ultrahyb™ hybridization buffer (Ambion, inc.).
After washing with 0.1x SSC, 0.1% SDS at 68°C, the membrane was exposed to film.
The same membrane was stripped by boiling in 0.1% SDS and re-hybridized with a human β-actin antisense riboprobe.
For analysis of multiple splice variants, total RNA samples (0. 
RESULTS
Constitutive and cell-specific regions of accessible chromatin associated with VEGF-A.
Our chromatin mapping studies encompassed a variety of cell types from man and rat, including both tumor lines and primary cells. The scope of this survey, as well as our choices for some of the cell types tested, was motivated by our goal of developing candidate ZFPs for a variety of pro-and anti-angiogenic gene therapies. We wished to identify any constitutive accessible chromatin regions in the VEGF-A promoter, as well as those specific to medically relevant target tissues and model organisms. We observed a total of four distinct hypersensitive regions. Two of these, centered on approximately bp -550 and +1 of the VEGF-A promoter, were invariably observed in every cell type tested. Fig. 1 shows typical experimental results identifying these regions in both man (Fig. 1A) and rat (Fig. 1B) . Both regions appear as doublets when viewed at higher resolution (e.g. Fig. 1, A and C) . The discovery of an open region at '+1' was somewhat expected, as hypersensitive regions are often observed in the vicinity of sites for transcription initiation (for a review, see (43)) and this region further contains conserved regulatory elements which have been shown to be important for VEGF-A activation including targets for SP1 and AP-2 (44). The observation in both man and rat of accessible chromatin in the '-550' region was somewhat more surprising, as no regulatory elements have thus far been mapped to this area of the VEGF-A promoter. Interestingly, though, this region exhibits a high degree of sequence conservation across all species for which VEGF-A promoter sequence is available (man, mouse and rat) (Fig. 1F, gray trace) , which becomes more pronounced when conservation is considered in terms of regulatory element-sized sequence blocks, (Fig.   1F , black trace). This suggests the possibility that as yet unidentified regulators of VEGF-A transcription may operate via binding to elements in this region. Initial studies in which a DNA fragment containing this region is fused to the promoter of a luciferase reporter indicate that this region exhibits cis-acting regulatory functions (data not shown), and the mapping and definition of the transcription factor-DNA interactions that occur on this DNA will be described elsewhere. We excluded the possibility that this DNA sequence itself was a more favored substrate for DNase 1 digestion by performing a control mapping study using purified naked genomic DNA that indicated no enhanced cutting of this region by DNase 1 (data not shown).
In addition to the constitutive hypersensitive regions found at -550 and +1, we identified two other stretches of accessible chromatin that were apparent in only a subset of the cells used in our studies. One of these regions encompassed approximately 300 bp centered on the hypoxia response element (HRE) of VEGF-A, and was observed in human primary skeletal muscle cells (Fig. 1C) and in the Hep3B cell line (data not shown). In contrast this site was clearly not observed in HEK293 cells (Fig. 1C) . The hypoxia response element encompasses a region of enhanced sequence conservation in the VEGF-A promoter (Fig. 1F) , and has been shown to contain several conserved regulatory elements that are required for induction of VEGF-A by hypoxia, including a binding site for HIF-1 (39, 45, 46 (Fig. 1D) , primary skeletal muscle cells (data not shown) and rat primary cardiac myocytes (Fig. 1B) . Interestingly, this region contains a putative SP1 binding site and is adjacent to an alternate transcription start site (47) (Fig. 1F ). This region also displayed the capacity to activate the expression of a reporter gene in cis (data not shown). In summary, these studies identified four regions of accessible chromatin within the promoter region of VEGF-A that were conserved in rat and man. Three of these, centered at approximately bp -550, +1, and +500 relative to the transcriptional start site, were found in HEK293 cells and were targeted for further studies with designed ZFPs. Collectively, these fingers provide a 'directory' of triplet-binding modules that may be freely mixed and matched to obtain multifinger proteins with desired binding properties.
Design and biochemical characterization of ZFPs targeted to open chromatin regions
In particular, we have found that when care is taken to preserve finger context the preferred targets of the resultant ZFPs are typically a composite of the component finger triplet specificities. Using this approach, we have designed ZFPs that recognize targets within the '-550', '+1' and '+500' open chromatin regions observed in HEK293 cells (Fig.   2D ), and assembled genes for these ZFPs. We have also included two control ZFPs targeted to sites outside of the hypersensitive regions. Designs for our ZFPs are shown in Table II . We have named the ZFPs according to their target location relative to the transcription start site of VEGF-A. Thus the first base in the target sequences of VZ-downstream, of the principal site of transcription initiation. One of our designs has two target sites in this region and so has been given a complex name to reflect this fact (VZ+42 / +530). Where there are multiple ZFPs targeted to a given sequence, this is indicated by the use of a small letter suffix at the end of each name to distinguish between alternate ZFP designs.
Genes for our ZFPs were assembled using previously described methods (17) and each protein was expressed in recombinant form (Fig. 2 , A and C). We then characterized the DNA-binding affinity of each ZFPs using a gel shift assay. Procedures for these studies were similar to those described previously (17) (for details see Experimental Procedures). We found that our designed ZFPs exhibited a range of apparent K d 's for their intended DNA targets, from 0.003 nM to 3 nM (Fig. 2E ). For comparison, under these conditions SP1, the parent ZFP for our designs, exhibited an apparent K d of 0.25 nM for its DNA target (Fig. 2E ). These studies demonstrated that each designed ZFP recognizes its target site with high affinity. (Fig. 3A) . The level of activation ranged between 3-to 15-fold.
Activation of the human VEGF-
The activation was ZFP-dependent; a fusion of Green Fluorescent Protein (50) with VP16 was unable to activate the reporter. This result showed that all of the designed ZFPs were active on a naked DNA template. There also appeared to be no strong correlation between the binding affinity of each ZFP and its capacity to transiently activate the VEGF-A promoter reporter from distant sites in the locus. (Fig.   3D ). In contrast to their variable activities, the ZFPs were found to be expressed to similar levels as determined by Western blot (Fig. 3E) and by Taqman for mRNA expression (Fig. 3F) . Therefore, the differential activity of the ZFP-VP16 fusions most likely is not related to differential ZFP expression.
Transcriptional activation of endogenous human VEGF-
We also compared the behavior of ZFPs targeted to the accessible regions of VEGF-A with two ZFPs targeted to inaccessible regions. Data for these studies is shown in Fig.   4 . Whereas all four ZFPs activated the naked reporter construct to approximately equal levels, a clear discrepancy was seen regarding activity against the endogenous VEGF-A gene. The accessible-region targeted ZFPs activated VEGF-A by factors of 4 to 5 while the ZFPs targeted to sites outside of the accessible regions showed no appreciable increase in VEGF-A expression level.
Activation of human VEGF-A gene by ZFPs fused with different activation domains. 
To achieve a higher level of VEGF-A activation by ZFPs in human cells, we tested the performance of other activation domains against that achieved by VP16 (data not shown). We found that the activation domain from the p65 subunit of NF-κB offered higher levels of activation when tested using several of our ZFPs (Fig. 5) . In this experiment, some ZFP-p65 fusions, for example the ZFP VZ+434b, induced a VEGF-A protein accumulation that was 3-to 4-fold higher than that induced by ZFP-VP16 fusions (Fig. 5C ), although the ZFP-p65 fusion proteins were expressed and accumulated in cells to similar levels as the ZFP-VP16 fusions (Fig. 5B) . The higher level of ZFP-p65 fusion induced VEGF-A protein production was consistent with a higher level of VEGF-A mRNA transcription as determined by Taqman analysis (Fig.5D) . Interestingly, for some ZFPs such as VZ+472, the p65 fusions displayed similar activities as the VP16 fusions. Therefore, it seems that VP16 and p65 have different target site-dependent activation mechanisms. individually activated VEGF-A protein production in HEK293 cells by 8 and 6 fold respectively. However, when they were co-transfected at a 1:1 ratio into the cells, the level of VEGF-A gene activation was enhanced (30-fold by ELISA) compared to the levels induced by each individual ZFP. A similar cooperation between ZFPs VZ+434b-p65 and VZ-573a-VP16 was also been observed (data not shown).
Cooperation between ZFPs for activation of human VEGF-
Comparison with levels of VEGF-A produced by hypoxia  In order to assess how our ZFP-activated levels of VEGF-A expression compared with the levels produced by physiologically relevant processes, we compared VEGF-A production induced by ZFP with that induced by hypoxia. For many ZFPs tested, for example ZFP VZ+434b, we found that the ZFPs were capable of activating VEGF-A expression to a level higher than that induced by hypoxia. As shown in Fig. 7 , HEK293 cells growing under hypoxic conditions had a 5-fold higher steady state VEGF-A mRNA level than under normoxic conditions (Fig. 7B) , and accumulated VEGF-A protein to nearly 400 pg/ml in medium (a 10-fold increase, Fig. 7A ). ZFP VZ+434b with p65 activation domain was able to activate VEGF-A gene 5-to 10-times further than that induced by hypoxia with an accumulation of VEGF-A protein in culture medium to nearly 4000 pg/ml (Fig. 7A) and a 20-fold increase in VEGF-A mRNA level (Fig. 7B) . This observation was also confirmed by Northern blot analysis (Fig. 7C) . Fig. 7D , the introduction of a single ZFP, the VZ+434b as either VP16 or p65 fusion, resulted a proportional increase in all of the splice variants.
DISCUSSION
In this study we have successfully designed a panel of ZFPs that bind with high affinity to diverse DNA sequences present within the VEGF-A locus (Fig. 2) and that are capable of activating expression of the endogenous human chromosomal VEGF-A gene (Figs. 3-7) . Our experimental approach incorporated information regarding the chromatin structure of the VEGF-A locus such that proteins were designed to sequences present within the DNase 1 hypersensitive regions ( Fig. 1 ) and this contributed to the large number of locations that we have identified from which designed transcription factors may activate VEGF-A (Figs. 3 and 4 ) relative to single targets described in previous studies (16) (17) (18) . We propose that ZFP targeting strategies that incorporate information regarding chromatin structure will provide a more efficient means for identifying artificial transcription factors capable of specifically regulating endogenous genes than strategies based on ZFP design principles alone. We find that several of these designed ZFPs are quite potent, yielding VEGF-A levels that exceed those induced by hypoxia (Fig. 7) . We speculate that the regulation of multiple VEGF-A splice variants will be of utility in somatic gene therapy approaches to cardiovascular disease (51-56).
Our panel of artificial transcription factors targeted to diverse sites in VEGF-A provides a unique tool for assessing the structural determinants of transcriptional activation at an endogenous locus, and several of our results may bear the signature of the transcriptional effects of chromatin structure. We find, for example, that our panel of ZFPs exhibits quite different patterns of activation when tested using the endogenous VEGF-A locus verses a naked promoter reporter construct (Fig. 3, compare B and C) .
They also differ depending on whether the site is within a DNase 1 accessible region or not (Fig. 4) . Furthermore, we observe that the ability of the p65 activation domain to outperform VP16 also varies in a target site-dependent manner, with relative activation levels varying over a factor of three depending on the location of the ZFP target within the VEGF-A locus (Fig. 5) . These effects highlight the role of structural context that is imposed by chromatin and the binding of other regulatory proteins on the capacity of transcription factors to activate an endogenous locus and also reemphasize the distinct regulatory and steric requirements of different activation domains to achieve optimal performance.
The capacity to generate a panel of designed transcription factors targeted to diverse sites in an endogenous locus also provides practical advantages in a variety of applications. In studying the effects of up-or downregulation of a target locus, for example, conclusions regarding gene function will be strongest if a given effect is observed repeatedly using multiple different regulators. In addition, for potential medical uses, the availability of multiple ZFP candidates provides a greater likelihood of finding one that yields optimal benefits with minimal side effects. Perhaps the most exciting possibilities for use of these proteins, however, lie in the study of transcriptional regulation. For example, the ability to target multiple activation domains to arbitrary sites in the same locus may have applications in the study of synergy. In this study we have taken the first steps to examine this issue, and have demonstrated enhanced effects on transcriptional activation mediated by cotransfected VP16-and p65 activation domain-bearing ZFPs. It seems reasonable to speculate that, by using larger combinations of appropriately targeted functional domains, our ZFPs may offer the prospect for total reconstitution of activation processes using completely defined components.
An additional observation of these studies is that ZFPs fused with the 268 amino acid activation domain of p65 (42) activate the endogenous VEGF-A gene as well as or better than the 78 aa activation domain of the Herpes simplex virus VP16 (41).
Although both VP16 and NF-κB p65 are strong acidic activation domains and share certain functional features (for example, recruitment of the ARC/DRIP complex and facilitated assembly of a preinitiation complex on promoter DNA (57,58)), differences in their transactivation mechanism have been reported. For example, the histone acetyltransferase activity of p300 has been demonstrated to be necessary for activation by NF-κB, but less essential for activation by VP16 (59, 60) . It is possible that the local availability of p300 or other coactivators in the endogenous VEGF-A locus may account for the differences we observed. Procedures". The levels of VEGF-A mRNA were normalized against GAPDH. E, The ZFP protein contents in the transfected cells were analyzed by Western blotting using anti-FLAG antibody (Sigma) which recognizes the FLAG epitope tag of the engineered ZFPs. F, The levels of ZFP mRNA in the transfected were determined by Taqman, and normalized against GAPDH mRNA levels. The primers and probe were designed to recognize the sequence encoding for the VP16 activation domain and FLAG tag. Ta rg e t S e q u e n ce ZF P N a m e S u bsite s F i n g e r D e sig n s
Ap p a re n t K d (n M ) 
